鸦胆子油口服乳液联合卡培他滨治疗晚期胃癌的临床研究
|
摘要
目的探讨鸦胆子油口服乳液联合卡培他滨片治疗晚期胃癌的临床疗效。方法选取2016年10月—2018年10月湖北医药学院附属襄阳市第一人民医院收治的100例晚期胃癌患者为研究对象,将所有患者随机分为对照组和治疗组,每组各50例。对照组患者入院后口服卡培他滨片,推荐剂量为1 250 mg/m~2,2次/d,早晚各1次;治疗组患者在对照组的基础上口服鸦胆子油口服乳液,1支/次,3次/d。两组患者均治疗4周。观察两组患者的临床疗效,同时比较两组治疗前后的KPS评分、肿瘤标志物、血清炎性因子水平和不良反应。结果治疗后,对照组客观缓解率(ORR)为54.00%,疾病控制率(DCR)为74.00%;治疗组客观缓解率为74.00%,疾病控制率为88.00%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组KPS评分明显升高,同组治疗前后比较差异具有统计学意义(P<0.05);且治疗后治疗组KPS评分明显高于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组糖类抗原199(CA199)、癌胚抗原(CEA)水平均显著降低,同组治疗前比较差异具有统计学意义(P<0.05);且治疗后治疗组CA199、CEA水平均明显低于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组白细胞介素-6(IL-6)、C反应蛋白(CRP)水平均显著降低,同组治疗前比较差异具有统计学意义(P<0.05);且治疗后治疗组IL-6、CRP水平均明显低于对照组,两组比较差异具有统计学意义(P<0.05)。治疗组患者粒细胞减少、肝功能异常、恶心呕吐和腹泻发生例数显著少于对照组(P<0.05)。结论鸦胆子油口服乳液联合卡培他滨片治疗晚期胃癌的临床疗效较好,能够改善患者生活质量,降低肿瘤标志物水平和血清炎症因子水平,具有一定的临床推广应用价值。
Objective To evaluate the efficacy of Yadanzi Oil Oral Emulsion combined with capecitabine in treatment of advanced gastric cancer. Methods Patients(100 cases) with advanced gastric cancer in Xiangyang No. 1 People's Hospital Affiliated Hospital of Hubei University of Medicine from October 2016 to October 2018 were randomly divided into control and treatment groups, and each group had 50 cases. Patients in the control group were po administered with Capecitabine Tablets, 1 250 mg/m~2, twice daily, once in the morning and once in the evening. Patients in the treatment group were po administered with Yadanzi Oil Oral Emulsion on the basis of control group, 1 tube/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacies were evaluated, and the KPS score, tumor marker levels, serum inflammatory factors levels, and adverse reactions in two groups before and after treatment were compared. Results After treatment, the objective remission rates(ORR) in the control and treatment groups were 54.00% and 74.00%, respectively, and the disease control rates(DCR) in the control and treatment groups were74.00% and 88.00%, respectively, and there was difference between two groups(P < 0.05). After treatment, the KPS scores in two groups were significantly increased, and there were differences in the same group(P < 0.05). After treatment, the KPS scores in the treatment group were significantly higher than those in the control group, with significant difference between two groups(P < 0.05).After treatment, the levels of CA199, CEA, IL-6, and CRP in two groups were significantly decreased, and there were differences in the same group(P < 0.05). And the tumor marker levels and serum inflammatory factors levels in the treatment group after treatment were significantly lower than those in the control group, with significant difference between two groups(P < 0.05). The incidences of granulocytopenia, abnormal liver function, nausea, vomiting and diarrhea in the treatment group were significantly lower than those in the control group(P < 0.05). Conclusion Yadanzi Oil Oral Emulsion combined with Capecitabine Tablets has a good clinical effect in treatment of advanced gastric cancer, can improve the quality of life of patients and reduce the levels of tumor markers and serum inflammatory factors, which has a certain clinical application value.
Objective To evaluate the efficacy of Yadanzi Oil Oral Emulsion combined with capecitabine in treatment of advanced gastric cancer. Methods Patients(100 cases) with advanced gastric cancer in Xiangyang No. 1 People's Hospital Affiliated Hospital of Hubei University of Medicine from October 2016 to October 2018 were randomly divided into control and treatment groups, and each group had 50 cases. Patients in the control group were po administered with Capecitabine Tablets, 1 250 mg/m~2, twice daily, once in the morning and once in the evening. Patients in the treatment group were po administered with Yadanzi Oil Oral Emulsion on the basis of control group, 1 tube/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacies were evaluated, and the KPS score, tumor marker levels, serum inflammatory factors levels, and adverse reactions in two groups before and after treatment were compared. Results After treatment, the objective remission rates(ORR) in the control and treatment groups were 54.00% and 74.00%, respectively, and the disease control rates(DCR) in the control and treatment groups were74.00% and 88.00%, respectively, and there was difference between two groups(P < 0.05). After treatment, the KPS scores in two groups were significantly increased, and there were differences in the same group(P < 0.05). After treatment, the KPS scores in the treatment group were significantly higher than those in the control group, with significant difference between two groups(P < 0.05).After treatment, the levels of CA199, CEA, IL-6, and CRP in two groups were significantly decreased, and there were differences in the same group(P < 0.05). And the tumor marker levels and serum inflammatory factors levels in the treatment group after treatment were significantly lower than those in the control group, with significant difference between two groups(P < 0.05). The incidences of granulocytopenia, abnormal liver function, nausea, vomiting and diarrhea in the treatment group were significantly lower than those in the control group(P < 0.05). Conclusion Yadanzi Oil Oral Emulsion combined with Capecitabine Tablets has a good clinical effect in treatment of advanced gastric cancer, can improve the quality of life of patients and reduce the levels of tumor markers and serum inflammatory factors, which has a certain clinical application value.
引文
[1]徐飚,王建明.胃癌流行病学研究[J].中华肿瘤防治杂志,2006,5(1):315-317.
[2]闫泽强,魏微.卡培他滨联合阿司匹林对SGC-7901细胞增殖的体外抑制作用[J].现代药物与临床,2017,6(3):341-343.
[3]张月琴.奥沙利铂联合卡培他滨化疗治疗进展期胃癌的疗效及安全性[J].中国医药导刊,2016,18(1):40-41.
[4]张晓飞,张福林.鸦胆子油口服乳液联合DCF方案化疗治疗晚期胃癌48例[J].陕西医学杂志,2012,41(9):1209-1211.
[5]杨学宁,吴一龙.实体瘤治疗疗效评价标准-RECIST[J].循证医学,2004,4(2):85-90.
[6]Mor V,Laliberte L,Morris J N,et al.The karnofsky performance status scale.An examination of its reliability and validity in a research setting[J].Cancer,1984,53(9):2002-2007.
[7]韩光锋.晚期胃癌的内科治疗现状和进展[J].实用肿瘤杂志,2017,4(32):574.
[8]秦叔逵,龚新雷.晚期胃癌化疗的现状和新进展[J].临床肿瘤学杂志,2006,7(9):641-652.
[9]章敏.卡培他滨联合奥沙利铂治疗老年晚期胃癌32例分析[J].肿瘤学杂志,2009,15(12):269-271.
[10]何峰,张小霞.奥沙利铂联合卡培他滨对胃癌患者的疗效及对免疫功能的影响[J].蚌埠医学院学报,2013,38(9):314-317.
[11]米哲涛,臧志方,张秀甫.鸦胆子油口服乳液联合放疗治疗食管癌效果观察[J].肿瘤研究与临床,2015,6(9):627-629.
[12]李再来.血清CRP、IL-6与典型肿瘤标志物检测用于胃癌患者中的临床有效性[J].临床检验杂志:电子版,2017,1(6):106.
[2]闫泽强,魏微.卡培他滨联合阿司匹林对SGC-7901细胞增殖的体外抑制作用[J].现代药物与临床,2017,6(3):341-343.
[3]张月琴.奥沙利铂联合卡培他滨化疗治疗进展期胃癌的疗效及安全性[J].中国医药导刊,2016,18(1):40-41.
[4]张晓飞,张福林.鸦胆子油口服乳液联合DCF方案化疗治疗晚期胃癌48例[J].陕西医学杂志,2012,41(9):1209-1211.
[5]杨学宁,吴一龙.实体瘤治疗疗效评价标准-RECIST[J].循证医学,2004,4(2):85-90.
[6]Mor V,Laliberte L,Morris J N,et al.The karnofsky performance status scale.An examination of its reliability and validity in a research setting[J].Cancer,1984,53(9):2002-2007.
[7]韩光锋.晚期胃癌的内科治疗现状和进展[J].实用肿瘤杂志,2017,4(32):574.
[8]秦叔逵,龚新雷.晚期胃癌化疗的现状和新进展[J].临床肿瘤学杂志,2006,7(9):641-652.
[9]章敏.卡培他滨联合奥沙利铂治疗老年晚期胃癌32例分析[J].肿瘤学杂志,2009,15(12):269-271.
[10]何峰,张小霞.奥沙利铂联合卡培他滨对胃癌患者的疗效及对免疫功能的影响[J].蚌埠医学院学报,2013,38(9):314-317.
[11]米哲涛,臧志方,张秀甫.鸦胆子油口服乳液联合放疗治疗食管癌效果观察[J].肿瘤研究与临床,2015,6(9):627-629.
[12]李再来.血清CRP、IL-6与典型肿瘤标志物检测用于胃癌患者中的临床有效性[J].临床检验杂志:电子版,2017,1(6):106.